

To: The Stakeholders of Eli Lilly and Company

1. Introduction and Objectives of Work

Bureau Veritas UK Ltd (Bureau Veritas) has been engaged by Eli Lilly and Company (Lilly) to provide limited assurance of select environmental data to be included in Lilly's 2025 Sustainability Report and CDP submission (collectively the 'Reports'). The objective is to provide assurance to Lilly and its stakeholders over the accuracy and reliability of the reported information and data.

2. Scope of Work

The scope of our work was limited to assurance over the following information included within the Reports for the period 1st January – 31st December 2025 (the 'Selected Information'):

- Water
 - Water withdrawals (billion litres)
 - Water recycling and reuse rate (%)
- 2030 Water Goal (%)
 - Ensuring 100% of Lilly sites meet predicted no-effect concentrations (PNEC) for pharmaceuticals in the environment
- Waste (metric tonnes)
 - Total Waste Generation
 - Hazardous waste
 - Non-hazardous waste
 - Total Waste Disposition
 - Beneficial use (includes recycled, reused, and waste-to-energy)
 - Treated (includes combustion without energy recovery)
 - Landfilled total
 - Waste Goal Metrics
 - Waste generated from routine operations
 - Waste to landfill
 - Plastic waste from routine operations
 - Plastic waste repurposed for beneficial use (includes recycled, reused and waste-to-energy)
 - Plastic waste recycled or reused
- 2030 Waste Goal (%)
 - Percentage of total waste from routine operations sent to landfill
 - Percentage of total plastic waste from routine operations repurposed for beneficial use
 - Percentage of total plastic waste from routine operations recycled or reused
- Scope 3 Greenhouse Gas (GHG) Emissions (mtCO₂)
 - Category 1: Purchased Goods and Services
 - Category 2: Capital Goods
 - Category 3: Fuel and Energy Related Activities
 - Category 4: Upstream Transportation and Distribution
 - Category 5: Waste Generated in Company Operations
 - Category 6: Business Travel
 - Category 7: Employee Commuting
 - Category 8: Upstream Leased Assets

- Category 9: Downstream Transportation and Distribution
- Category 10: Processing of Sold Products
- Category 11: Use of Sold Products
- Category 12: End of Life Treatment of Sold Products
- Category 13: Downstream Leased Assets
- Category 14: Franchises
- Category 15: Investments

3. Reporting Criteria

The Selected Information needs to be read and understood together with Lilly's Basis of Reporting for Key Environmental Sustainability Indicators document on the link: https://assets.ctfassets.net/Eli_Lilly_Basis_of_Reporting, as well as Lilly's internal Corporate Goals Scope Documents, Scope 3 Inventory Management Plan (IMP), the definitions and assumptions considered therein and the notes and disclosures on the link: <https://sustainability.lilly.com/environmental>.

4. Limitations and Exclusions

Excluded from the scope of our work is assurance of information relating to:

- Activities outside the defined assurance period;
- Positional statements of a descriptive or interpretative nature, or of opinion, belief, aspiration, or commitment to undertake future actions;
- Other information included in the Reports other than the Selected Information;
- The waste data accounting process covering different waste streams is based on internal criteria/ classifications defined by Lilly. The verification scope does not cover the review of end-of-life treatment for the reported waste data;
- Any financial data feeding into the Selected Information, such as but not limited to spend data input for Scope 3 Categories 1, 2, and 15 calculations; and
- Select input data obtained via external websites/references, internal data portal (Power BI) and activity data assured by third-party were checked for alignment and not traced back to primary sources. These includes (but not limited to) estimation of supplier specific emission factors and energy & fuel data accounted under Scope 3 Category 3.

The following limitations should be noted:

- This limited assurance engagement relies on a risk based selected sample of sustainability data and the associated limitations that this entails;
- The reliability of the reported data is dependent on the accuracy of metering and other production measurement arrangements employed at site level, not addressed as part of this assurance;
- This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist;
- Verification of Lilly's sites meeting predicted no-effect concentrations (PNEC) was limited to assessing and reviewing internal controls, monitoring parameters and limits/ standards/ guidelines set out at selected sampled sites; and
- Limitations observed on the availability of rail travel data, usage of long-haul premium economy Emissions Factors for all flight travel covered under Scope 3 Category 6. These are not considered to have any material impact on the Selected Information.

5. Responsibilities

This preparation and presentation of the Selected Information in the Reports are the sole responsibility of the management of Lilly.

Bureau Veritas was not involved in the drafting of the Reports or of the Reporting Criteria. Our responsibilities were to:

- Obtain limited assurance about whether the Selected Information has been prepared in accordance with the Reporting Criteria;
- Form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- Report our conclusions to the Directors of Lilly.

6. Assessment Standard

We performed our work to a limited level of assurance in accordance with International Standard on Assurance Engagements (ISAE) 3000 Revised, Assurance Engagements Other than Audits or Reviews of Historical Financial Information (effective for assurance reports dated on or after December 15, 2015), issued by the International Auditing and Assurance Standards Board.

7. Summary of Work Performed

As part of our independent assurance, our work included:

1. Conducting interviews with relevant personnel of Lilly;
2. Reviewing the data collection and consolidation processes used to compile Selected Information, including assessing assumptions made, and the data scope and reporting boundaries;
3. Reviewing documentary evidence provided by Lilly;
4. Agreeing a selection of the Selected Information to the corresponding source documentation;
5. Reviewing Lilly systems for quantitative data aggregation and analysis;
6. Assessing the disclosure and presentation of the Selected Information to ensure consistency with assured information;
7. Conducting detailed sampling for selected sites for Waste (Sesto, PR01/PR05, Indy FM, LRL-Protomer-Pasadena) and for Water (Cork SSC, Limerick, LCC, Concord);
8. Reperforming GHG emissions conversions calculations;
9. Confirmation of accuracy of information with third party engaged by Lilly for accounting and reporting its GHG data; and
10. Reperforming (a selection of) aggregation calculations of the Selected Information.

A 5% materiality threshold was applied to this assurance. It should be noted that the procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

8. Conclusion

On the basis of our methodology and the activities, limitations and exclusions described above nothing has come to our attention to indicate that the Selected Information in the table below is not fairly stated in all material respects.

Metric	Verified Value*
Water	
Water intake (billion litres)	9.20
Water recycled and reuse rate (%)	96.8%

2030 Water Goal (%)	
Ensuing 100% of Lilly sites meet predicted no-effect concentrations (PNEC) for pharmaceuticals in the environment	100%
Waste (metric tonnes)	
Non-hazardous waste	104,000
Hazardous waste	44,000
Total waste generation	148,000
Total Waste Disposition (metric tonnes)	
Beneficial use (recycled, reused, and waste-to-energy)	129,000
Treated (includes combustion without energy recovery)	17,000
Landfilled	2,600
Waste Goal Metrics (metric tonnes)**	
Waste generated from routine operations	133,000
Waste from routine operations to landfill	900
Plastic waste from routine operations	11,500
Plastic waste from routine operations repurposed for beneficial use (recycled, reused and waste-to-energy)	11,000
Plastic waste from routine operations recycled or reused	9,600
2030 Waste Goal (%)	
Percentage of total waste from routine operations sent to landfill	0.7%
Percentage of total plastic waste from routine operations repurposed for beneficial use	96.0%
Percentage of total plastic waste from routine operations recycled or reused	83.7%
Scope 3 GHG Emissions (metric tonnes CO2e)	
Category 1: Purchased Goods and Services	5,650,000
Category 2: Capital Goods	1,110,000
Category 3: Fuel and Energy Related Activities	127,000
Category 4: Upstream Transportation and Distribution	1,060,000
Category 5: Waste Generated in Company Operations	24,000
Category 6: Business Travel	85,200
Category 7: Employee Commuting	34,700
Category 8: Upstream Leased Assets	Not Relevant, Not Calculated
Category 9: Downstream Transportation and Distribution	150
Category 10: Processing of Sold Products	Not Relevant, Not Calculated
Category 11: Use of Sold Products	Not Relevant, Not Calculated
Category 12: End of Life Treatment of Sold Products	120,000
Category 13: Downstream Leased Assets	Not Relevant, Not Calculated
Category 14: Franchises	Not Relevant, Not Calculated
Category 15: Investments	6,800
Total Scope 3 GHG Emissions***	8,220,000

*Values have been rounded to the closest significant whole number for the purpose of representation wherever applicable.

**Certain waste categories classified as non-routine waste are excluded in the reported data and calculations, for further details refer <https://sustainability.lilly.com/>.

***Covering selected Scope 3 categories reported above.

9. Statement of Independence, Integrity and Competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 190 years history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes. Bureau Veritas operates a certified¹ Quality Management System which complies with the requirements of ISO 9001:2015, and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards, quality reviews and applicable legal and regulatory requirements which we consider to be equivalent to ISQM 1 & 2².

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)³, across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities. We consider this to be equivalent to the requirements of the IESBA code⁴. The assurance team for this work does not have any involvement in any other Bureau Veritas projects with Lilly.



Bureau Veritas UK Ltd

Registered in England & Wales, Company Number: 1758622

Registered Office: Suite 206 Fort Dunlop, Fort Parkway, Birmingham, B24 9FD

London, 14th July 2026

¹ Certificate available on request

² International Standard on Quality Management 1 (Previously International Standard on Quality Control 1) & International Standard on Quality Management 2

³ International Federation of Inspection Agencies – Compliance Code – Third Edition

⁴ Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants